Short Trials Found Almost Nothing for MS Spasticity. Longer Trials Found More. The Numbers Need Care.
A nine-trial meta-analysis of 2,544 patients speaks to how long cannabis takes to work for MS spasticity, finding no statistically significant benefit in short-duration trials and much larger effects in longer ones. The pooled magnitudes are not usable,…
Relief Is Not the Same as Slowing a Disease: What Cannabis Trials Have Actually Measured
The trials on cannabis and disease progression answer a question patients ask constantly: will this change where my illness is heading, or only make it easier to live with? A three-year randomized trial in progressive multiple sclerosis found no effect…
Nabiximols vs. Cannabis Decoction for MS Spasticity: What a New Formulation Comparison Study Found
The nabiximols discontinuation MS spasticity study highlights that most patients eventually stop nabiximols, with some switching to cannabis decoction experiencing further symptom improvement and fewer side effects. This retrospective cohort provides…
2026 Review: Cannabinoids in Managing MS Spasticity
This 2026 systematic review evaluates cannabinoids for MS spasticity, finding modest improvements with THC:CBD extracts. Despite low evidence certainty, cannabinoids may aid some patients with MS spasticity as adjunctive therapy. Careful clinical…
Cannabinoids for MS Spasticity: What 27 Randomized Trials Show
cannabinoids for MS spasticity: A systematic review of 27 randomized trials found modest patient-reported improvement in multiple-sclerosis spasticity, especially with THC:CBD extracts. Objective benefits were limited and the certainty of evidence was…
Nabiximols for MS: What a New Meta-Analysis Shows Beyond Spasticity
nabiximols multiple sclerosis: A June 25, 2026 meta-analysis pooling 2,949 multiple sclerosis patients found nabiximols linked to significant improvement in bladder function, sleep disruption, spasm quality, and gait beyond its approved spasticity use.…
The Endocannabinoid System and Myelin Regeneration: A Clinical Breakdown
A new preclinical study from Complutense University has found that CB1 receptor myelin repair mechanisms depend on intact endocannabinoid signaling at a critical cellular window. Researchers removed CB1 receptors specifically from newly formed…
Long-Term Cannabis Therapy May Change MS Spasticity Outcomes
Cannabis for MS spasticity was associated with meaningful symptom improvement in a new meta-analysis involving 2,544 multiple sclerosis patients across nine trials. The strongest benefits emerged with longer treatment duration, while short-term effects…
Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.
A new consensus from Italian neurologists proposes enhancing the endocannabinoid system multiple sclerosis treatment approach for patients with relapse-free disease. The algorithm combines cannabinoid agents with lifestyle interventions to address…
Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis.
A real-time smartphone-based study of 258 MS patients revealed that higher pain levels drive increased cannabis use and decreased alcohol consumption. This research using ecological momentary assessment provides clinical evidence that MS patients make…